Lineage Cell Therapeutics shares fall 1.20% after-hours following the initiation of a new islet cell transplant program in Type 1 Diabetes.

Lineage Cell Therapeutics, Inc. declined 1.20% in after-hours trading. The company announced the initiation of a new islet cell transplant program in Type 1 Diabetes (T1D), aiming to address the issue of large-scale production of islet cells. This news suggests a potential breakthrough in commercializing islet cell therapy product candidates, which could be seen as a positive development for the company. However, the stock's decline may be due to other market factors or investor sentiment not directly related to the news event.